DHFR: A promising drug target for the identification of antimalarial agents
DOI:
https://doi.org/10.63682/jns.v14i32S.7941Keywords:
Plasmodium falciparum, malaria, Dihydrofolate reductase, resistanceAbstract
Malaria continues to be a significant worldwide health concern, characterized by a substantial illness burden and fatality rate. The escalating resistance of Plasmodium falciparum to standard antimalarial medications highlights the pressing need for novel therapeutic approaches. Dihydrofolate reductase (DHFR) is a prominent therapeutic target in malaria, serving as a crucial enzyme in the folate biosynthesis pathway, which is important for the replication and survival of the parasite's DNA. Nonetheless, extensive resistance to antifolates such as pyrimethamine has emerged due to point mutations in the dhfr gene. This has resulted in a revitalized focus on creating innovative DHFR inhibitors that are efficacious against resistant strains. Recent advancements in medicinal chemistry and structure-based drug design have enabled the identification of novel molecules with enhanced affinity for mutant DHFR variants. The present review examines malaria incidence, resistance mechanisms, and highlights DHFR as a crucial target for the development of next-generation antimalarials..
Downloads
Metrics
References
Sato S (2021) Plasmodium—a brief introduction to the parasites causing human malaria and their basic biology. Journal of Physiological Anthropology 40 (1):1. doi:10.1186/s40101-020-00251-9
. Venkatesan P (2025) WHO world malaria report 2024. The Lancet Microbe 6 (4). doi:10.1016/j.lanmic.2025.101073
. Siciliano G, Alano P (2015) Enlightening the malaria parasite life cycle: bioluminescent Plasmodium in fundamental and applied research. Volume 6 - 2015. doi:10.3389/fmicb.2015.00391
Addissouky TA (2025) Artemisinin and its derivatives throughout the therapeutic mechanisms and clinical potential. Discover Chemistry 2 (1):10. doi:10.1007/s44371-025-00084-4
Fairhurst RM, Nayyar GML, Breman JG, Hallett R, Vennerstrom JL, Duong S, Ringwald P, Wellems TE, Plowe CV, Dondorp AM (2012) Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. The American journal of tropical medicine and hygiene 87 (2):231-241. doi:10.4269/ajtmh.2012.12-0025
. Kokori E, Olatunji G, Akinboade A, Akinoso A, Egbunu E, Aremu SA, Okafor CE, Oluwole O, Aderinto N (2024) Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts. Malaria Journal 23 (1):25. doi:10.1186/s12936-024-04844-y
. Winstanley P, Ward S (2006) Malaria chemotherapy. Advances in parasitology 61:47-76. doi:10.1016/s0065-308x(05)61002-0
. Assi S-B, Aba YT, Yavo JC, Nguessan AF, Tchiekoi NcB, San KM, Bissagnéné E, Duparc S, Lameyre V, Tanoh MA (2017) Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d’Ivoire. Malaria Journal 16 (1):8. doi:10.1186/s12936-016-1655-1
. Ogutu B, Yeka A, Kusemererwa S, Thompson R, Tinto H, Toure AO, Uthaisin C, Verma A, Kibuuka A, Lingani M, Lourenço C, Mombo-Ngoma G, Nduba V, N'Guessan TL, Nassa GJW, Nyantaro M, Tina LO, Singh PK, El Gaaloul M, Marrast AC, Chikoto H, Csermak K, Demin I, Mehta D, Pathan R, Risterucci C, Su G, Winnips C, Kaguthi G, Fofana B, Grobusch MP (2023) Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial. The Lancet Infectious Diseases 23 (9):1051-1061. doi:10.1016/S1473-3099(23)00209-8
. Schmitt EK, Ndayisaba G, Yeka A, Asante KP, Grobusch MP, Karita E, Mugerwa H, Asiimwe S, Oduro A, Fofana B, Doumbia S, Su G, Csermak Renner K, Venishetty VK, Sayyed S, Straimer J, Demin I, Barsainya S, Boulton C, Gandhi P (2022) Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 74 (10):1831-1839. doi:10.1093/cid/ciab716
Laurens MB (2020) RTS,S/AS01 vaccine (Mosquirix™): an overview. Human vaccines & immunotherapeutics 16 (3):480-489. doi:10.1080/21645515.2019.1669415
. Datoo MS, Dicko A, Tinto H, Ouédraogo J-B, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood BM, Ewer KJ, Bradley J, Kulkarni PS, Shaligram U, Hill AVS, Mahamar A, Sanogo K, Sidibe Y, Diarra K, Samassekou M, Attaher O, Tapily A, Diallo M, Dicko OM, Kaya M, Maguiraga SO, Sankare Y, Yalcouye H, Diarra S, Niambele SM, Thera I, Sagara I, Sylla M, Dolo A, Misidai N, Simando S, Msami H, Juma O, Gutapaka N, Paul R, Mswata S, Sasamalo I, Johaness K, Sultan M, Alexander A, Kimaro I, Lwanga K, Mtungwe M, Khamis K, Rugarabam L, Kalinga W, Mohammed M, Kamange J, Msangi J, Mwaijande B, Mtaka I, Mhapa M, Mlaganile T, Mbaga T, Yerbanga RS, Samtouma W, Sienou AA, Kabre Z, Ouedraogo WJM, Yarbanga GAB, Zongo I, Savadogo H, Sanon J, Compaore J, Kere I, Yoni FL, Sanre TM, Ouattara SB, Provstgaard-Morys S, Woods D, Snow RW, Amek N, Ngetsa CJ, Ochola-Oyier LI, Musyoki J, Munene M, Mumba N, Adetifa UJ, Muiruri CM, Mwawaka JS, Mwaganyuma MH, Ndichu MN, Weya JO, Njogu K, Grant J, Webster J, Lakhkar A, Ido NFA, Traore O, Tahita MC, Bonko MdA, Rouamba T, Ouedraogo DF, Soma R, Millogo A, Ouedraogo E, Sorgho F, Konate F, Valea I (2024) Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet 403 (10426):533-544. doi:10.1016/S0140-6736(23)02511-4
. Elliott DA, McIntosh MT, Hosgood HD, 3rd, Chen S, Zhang G, Baevova P, Joiner KA (2008) Four distinct pathways of hemoglobin uptake in the malaria parasite Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 105 (7):2463-2468. doi:10.1073/pnas.0711067105
. Herraiz T, Guillén H, González-Peña D, Arán VJ (2019) Antimalarial Quinoline Drugs Inhibit β-Hematin and Increase Free Hemin Catalyzing Peroxidative Reactions and Inhibition of Cysteine Proteases. Scientific Reports 9 (1):15398. doi:10.1038/s41598-019-51604-z
. Phillips MA, Rathod PK (2010) Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infectious disorders drug targets 10 (3):226-239. doi:10.2174/187152610791163336
. Hoelz LVB, A. CF, C. NM, S. PLC, and Boechat N (2018) Plasmodium Falciparum Dihydroorotate Dehydrogenase: A Drug Target against Malaria. Future Medicinal Chemistry 10 (15):1853-1874. doi:10.4155/fmc-2017-0250
. Siregar JE, Kurisu G, Kobayashi T, Matsuzaki M, Sakamoto K, Mi-ichi F, Watanabe Y-i, Hirai M, Matsuoka H, Syafruddin D, Marzuki S, Kita K (2015) Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex. Parasitology International 64 (3):295-300. doi:https://doi.org/10.1016/j.parint.2014.09.011
. Vaidya AB, Mather MW (2000) Atovaquone resistance in malaria parasites. Drug Resistance Updates 3 (5):283-287. doi:https://doi.org/10.1054/drup.2000.0157
. Llanos-Cuentas A, Casapia M, Chuquiyauri R, Hinojosa JC, Kerr N, Rosario M, Toovey S, Arch RH, Phillips MA, Rozenberg FD, Bath J, Ng CL, Cowell AN, Winzeler EA, Fidock DA, Baker M, Möhrle JJ, Hooft van Huijsduijnen R, Gobeau N, Araeipour N, Andenmatten N, Rückle T, Duparc S (2018) Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. The Lancet Infectious diseases 18 (8):874-883. doi:10.1016/s1473-3099(18)30309-8
. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B (2002) Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419 (6906):498-511. doi:10.1038/nature01097
. Wilson RJ, Denny PW, Preiser PR, Rangachari K, Roberts K, Roy A, Whyte A, Strath M, Moore DJ, Moore PW, Williamson DH (1996) Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. Journal of molecular biology 261 (2):155-172. doi:10.1006/jmbi.1996.0449
. Gardner MJ, Bates PA, Ling IT, Moore DJ, McCready S, Gunasekera MB, Wilson RJ, Williamson DH (1988) Mitochondrial DNA of the human malarial parasite Plasmodium falciparum. Molecular and biochemical parasitology 31 (1):11-17. doi:10.1016/0166-6851(88)90140-5
. Shears MJ, Botté CY, McFadden GI (2015) Fatty acid metabolism in the Plasmodium apicoplast: Drugs, doubts and knockouts. Molecular and biochemical parasitology 199 (1-2):34-50. doi:10.1016/j.molbiopara.2015.03.004
. Sparr C, Purkayastha N, Kolesinska B, Gengenbacher M, Amulic B, Matuschewski K, Seebach D, Kamena F (2013) Improved Efficacy of Fosmidomycin against Plasmodium and Mycobacterium Species by Combination with the Cell-Penetrating Peptide Octaarginine. 57 (10):4689-4698. doi:doi:10.1128/aac.00427-13
. Lell B, Ruangweerayut R, Wiesner J, Missinou MA, Schindler A, Baranek T, Hintz M, Hutchinson D, Jomaa H, Kremsner PG (2003) Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrobial agents and chemotherapy 47 (2):735-738. doi:10.1128/aac.47.2.735-738.2003
. Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, Matsiegui P-B, Binder R, Lell B, Wiesner J, Baranek T, Jomaa H, Kremsner PG (2002) Fosmidomycin for malaria. The Lancet 360 (9349):1941-1942. doi:https://doi.org/10.1016/S0140-6736(02)11860-5
Dahl EL, Rosenthal PJ (2007) Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrobial agents and chemotherapy 51 (10):3485-3490. doi:10.1128/aac.00527-07
Okada M, Guo P, Nalder SA, Sigala PA (2020) Doxycycline has distinct apicoplast-specific mechanisms of antimalarial activity. eLife 9. doi:10.7554/eLife.60246
. Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A, Upton LM, Abraham TS, Almeida MJ, Pradhan A, Porzelle A, Luksch T, Martínez MS, Luksch T, Bolscher JM, Woodland A, Norval S, Zuccotto F, Thomas J, Simeons F, Stojanovski L, Osuna-Cabello M, Brock PM, Churcher TS, Sala KA, Zakutansky SE, Jiménez-Díaz MB, Sanz LM, Riley J, Basak R, Campbell M, Avery VM, Sauerwein RW, Dechering KJ, Noviyanti R, Campo B, Frearson JA, Angulo-Barturen I, Ferrer-Bazaga S, Gamo FJ, Wyatt PG, Leroy D, Siegl P, Delves MJ, Kyle DE, Wittlin S, Marfurt J, Price RN, Sinden RE, Winzeler EA, Charman SA, Bebrevska L, Gray DW, Campbell S, Fairlamb AH, Willis PA, Rayner JC, Fidock DA, Read KD, Gilbert IH (2015) A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 522 (7556):315-320. doi:10.1038/nature14451
. Khandelwal A, Arez F, Alves PM, Badolo L, Brito C, Fischli C, Fontinha D, Oeuvray C, Prudêncio M, Rottmann M, Wilkins J, Yalkinoglu Ö, Bagchus WM, Spangenberg T (2022) Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside. Malaria Journal 21 (1):151. doi:10.1186/s12936-022-04171-0
. Gaillard T, Madamet M, Pradines B (2015) Tetracyclines in malaria. Malaria Journal 14 (1):445. doi:10.1186/s12936-015-0980-0
. Spillman NJ, Kirk K (2015) The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs. International journal for parasitology Drugs and drug resistance 5 (3):149-162. doi:10.1016/j.ijpddr.2015.07.001
. Barnes CBG, Dans MG, Jonsdottir TK, Crabb BS, Gilson PR (2022) PfATP4 inhibitors in the Medicines for Malaria Venture Malaria Box and Pathogen Box block the schizont-to-ring transition by inhibiting egress rather than invasion. Volume 12 - 2022. doi:10.3389/fcimb.2022.1060202
. Rachuri S, Nepal B, Shukla A, Ramanathan A, Morrisey JM, Daly T, Mather MW, Bergman LW, Kortagere S, Vaidya AB (2025) Mutational analysis of an antimalarial drug target, PfATP4. 122 (2):e2403689122. doi:doi:10.1073/pnas.2403689122
. Bouwman SAM, Zoleko-Manego R, Renner KC, Schmitt EK, Mombo-Ngoma G, Grobusch MP (2020) The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound. Travel Medicine and Infectious Disease 36:101765. doi:https://doi.org/10.1016/j.tmaid.2020.101765
. Gaur AH, Panetta JC, Smith AM, Dallas RH, Freeman BB, 3rd, Stewart TB, Tang L, John E, Branum KC, Patel ND, Ost S, Heine RN, Richardson JL, Hammill JT, Bebrevska L, Gusovsky F, Maki N, Yanagi T, Flynn PM, McCarthy JS, Chalon S, Guy RK (2022) Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. EBioMedicine 80:104065. doi:10.1016/j.ebiom.2022.104065
. Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, Smith AM, Stewart TB, Branum KC, Freeman BB, Patel ND, John E, Chalon S, Ost S, Heine RN, Richardson JL, Christensen R, Flynn PM, Van Gessel Y, Mitasev B, Möhrle JJ, Gusovsky F, Bebrevska L, Guy RK (2020) Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. The Lancet Infectious Diseases 20 (8):964-975. doi:https://doi.org/10.1016/S1473-3099(19)30611-5
. Zhang Z, Lyu M, Han X, Bandara S, Cui M, Istvan ES, Geng X, Tringides ML, Gregor WD, Miyagi M, Oberstaller J, Adams JH, Zhang Y, Nieman MT, von Lintig J, Goldberg DE, Yu EW (2024) The Plasmodium falciparum NCR1 transporter is an antimalarial target that exports cholesterol from the parasite's plasma membrane. Science advances 10 (51):eadq6651. doi:10.1126/sciadv.adq6651
. Garten M, Beck JR, Roth R, Tenkova-Heuser T, Heuser J, Istvan ES, Bleck CKE, Goldberg DE, Zimmerberg J (2020) Contacting domains segregate a lipid transporter from a solute transporter in the malarial host–parasite interface. Nature Communications 11 (1):3825. doi:10.1038/s41467-020-17506-9
. Popovici J, Tebben K, Witkowski B, Serre D (2021) Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters. International Journal for Parasitology: Drugs and Drug Resistance 15:36-42. doi:https://doi.org/10.1016/j.ijpddr.2020.12.004
. Ebstie YA, Abay SM, Tadesse WT, Ejigu DA (2016) Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug design, development and therapy 10:2387-2399. doi:10.2147/dddt.S61443
. Peters AL, Van Noorden CJ (2009) Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 57 (11):1003-1011. doi:10.1369/jhc.2009.953828
. Huang Z, Li R, Tang T, Ling D, Wang M, Xu D, Sun M, Zheng L, Zhu F, Min H, Boonhok R, Ding Y, Wen Y, Chen Y, Li X, Chen Y, Liu T, Han J, Miao J, Fang Q, Cao Y, Tang Y, Cui J, Xu W, Cui L, Zhu J, Wong G, Li J, Jiang L (2020) A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1. Cell Discovery 6 (1):93. doi:10.1038/s41421-020-00215-4
. Amusengeri A, Tata RB, Tastan Bishop Ö (2020) Understanding the Pyrimethamine Drug Resistance Mechanism via Combined Molecular Dynamics and Dynamic Residue Network Analysis. 25 (4):904
. Sirawaraporn W, Prapunwattana P, Sirawaraporn R, Yuthavong Y, Santi DV (1993) The dihydrofolate reductase domain of Plasmodium falciparum thymidylate synthase-dihydrofolate reductase. Gene synthesis, expression, and anti-folate-resistant mutants. Journal of Biological Chemistry 268 (29):21637-21644. doi:https://doi.org/10.1016/S0021-9258(20)80589-4
. Tanomsing N, Imwong M, Theppabutr S, Pukrittayakamee S, Day NP, White NJ, Snounou G (2010) Accurate and sensitive detection of Plasmodium species in humans by use of the dihydrofolate reductase-thymidylate synthase linker region. Journal of clinical microbiology 48 (10):3735-3737. doi:10.1128/jcm.00898-10
. Decharuangsilp S, Arwon U, Sooksai N, Rattanajak R, Saeyang T, Vitsupakorn D, Vanichtanankul J, Yuthavong Y, Kamchonwongpaisan S, Hoarau M (2024) Novel flexible biphenyl PfDHFR inhibitors with improved antimalarial activity. RSC medicinal chemistry 15 (7):2496-2507. doi:10.1039/d4md00197d
Remcho TP, Guggilapu SD, Cruz P, Nardone GA, Heffernan G, O'Connor RD, Bewley CA, Wellems TE, Lane KD (2020) Regioisomerization of Antimalarial Drug WR99210 Explains the Inactivity of a Commercial Stock. Antimicrobial agents and chemotherapy 65 (1). doi:10.1128/aac.01385-20
. Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, McLennan DN, White KL, Vivas L, Bongard E, Thongphanchang C, Taweechai S, Vanichtanankul J, Rattanajak R, Arwon U, Fantauzzi P, Yuvaniyama J, Charman WN, Matthews D (2012) Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proceedings of the National Academy of Sciences of the United States of America 109 (42):16823-16828. doi:10.1073/pnas.1204556109
. Biamonte MA, Wanner J, Le Roch KG (2013) Recent advances in malaria drug discovery. Bioorganic & medicinal chemistry letters 23 (10):2829-2843. doi:10.1016/j.bmcl.2013.03.067
. Hastings MD, Sibley CH (2002) Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. 99 (20):13137-13141. doi:doi:10.1073/pnas.182295999
. Hoarau M, Sermmai P, Varatthan T, Thiabma R, Jantra T, Rattanajak R, Vitsupakorn D, Vanichtanankul J, Saepua S, Yuthavong Y, Thongpanchang C, Kamchonwongpaisan S (2023) Discovery of rigid biphenyl Plasmodium falciparum DHFR inhibitors using a fragment linking strategy. RSC medicinal chemistry 14 (9):1755-1766. doi:10.1039/d3md00242j
. Ibraheem W, A. MA, and Alzain AA (2023) Phthalide derivatives as dihydrofolate reductase inhibitors for malaria: molecular docking and molecular dynamics studies. Journal of Biomolecular Structure and Dynamics 41 (11):5127-5137. doi:10.1080/07391102.2022.2080114
. Tarnchompoo B, Chitnumsub P, Jaruwat A, Shaw PJ, Vanichtanankul J, Poen S, Rattanajak R, Wongsombat C, Tonsomboon A, Decharuangsilp S, Anukunwithaya T, Arwon U, Kamchonwongpaisan S, Yuthavong Y (2018) Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance. ACS medicinal chemistry letters 9 (12):1235-1240. doi:10.1021/acsmedchemlett.8b00389
. Blasco B, Leroy D, Fidock DA (2017) Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nature medicine 23 (8):917-928. doi:10.1038/nm.4381
. Plowe CV (2022) Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malaria Journal 21 (1):104. doi:10.1186/s12936-022-04115-8
. Leski TA, Taitt CR, Colston SM, Bangura U, Holtz A, Yasuda CY, Reynolds ND, Lahai J, Lamin JM, Baio V, Ansumana R, Stenger DA, Vora GJ (2022) Prevalence of malaria resistance-associated mutations in Plasmodium falciparum circulating in 2017–2018, Bo, Sierra Leone. Volume 13 - 2022. doi:10.3389/fmicb.2022.1059695
. Hamel MJ, Poe A, Bloland P, McCollum A, Zhou Z, Shi YP, Ouma P, Otieno K, Vulule J, Escalante A, Udhayakumar V, Slutsker L (2008) Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. Transactions of the Royal Society of Tropical Medicine and Hygiene 102 (4):338-345. doi:10.1016/j.trstmh.2008.01.018
. Ahmed A, Das MK, Dev V, Saifi MA, Wajihullah, Sharma YD (2006) Quadruple mutations in dihydrofolate reductase of Plasmodium falciparum isolates from Car Nicobar Island, India. Antimicrobial agents and chemotherapy 50 (4):1546-1549. doi:10.1128/aac.50.4.1546-1549.2006
. Jovel IT, Mejía RE, Banegas E, Piedade R, Alger J, Fontecha G, Ferreira PE, Veiga MI, Enamorado IG, Bjorkman A, Ursing J (2011) Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America. Malaria Journal 10 (1):376. doi:10.1186/1475-2875-10-376
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
